Bayer receives MHRA approval for Kerendia® (finerenone) in adults with heart failure with LVEF ≥ 40 %
Sănătate
From Bayer PLC Apr 13 2026 The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Kerendia ® (finerenone), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40 %, in adults in the UK. The new indication covers both the heart failure phenotypes of heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with
astăzi